Literature DB >> 16858571

How do I treat and follow my TUNA patients.

Sas Barmoshe1, Alexandre R Zlotta.   

Abstract

Transurethral needle ablation (TUNA) of the prostate is an alternative treatment for benign prostatic hyperplasia (BPH) generating temperatures around 100 degrees C leading to necrotic lesions inside the prostate. TUNA is a minimally invasive, low morbidity associated, approach that uses radiofrequency energy. The needles are covered by teflon shields that protect the urethra from thermal injury. Since the introduction of TUNA, there has been a constant upgrading of the device to improve treatment quality. The main advantage of this therapy is the possibility of an outpatient care due to its anaesthesia-free option with a prostatic block. Catheterisation after the procedure is required in 10-40% of cases. Long-term data (5 years) on TUNA demonstrate a sustained improvement of both IPSS score and urinary flow. About a quarter of patients require further intervention at 5 years' follow-up. The safety profile, along with the significant improvement in both objective and subjective parameters observed after TUNA, makes it an attractive approach for symptomatic BPH.

Entities:  

Mesh:

Year:  2006        PMID: 16858571     DOI: 10.1007/s00345-006-0091-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Medical management of benign prostatic hyperplasia--are two drugs better than one?

Authors:  E Darracott Vaughan
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

2.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.

Authors:  Alexandre R Zlotta; Xenofon Giannakopoulos; Odd Maehlum; Tonnes Ostrem; Claude C Schulman
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

Review 3.  Laser therapy for benign prostatic hyperplasia: a review of recent developments.

Authors:  Tevita F Aho; Peter J Gilling
Journal:  Curr Opin Urol       Date:  2003-01       Impact factor: 2.309

4.  Transurethral Needle Ablation of the prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention.

Authors:  L M Harewood; L K Cleeve; H E O'Connell; A J Pope; M G Vaughan; D Agarwal
Journal:  J Endourol       Date:  1995-10       Impact factor: 2.942

5.  Comorbidities and perioperative complications among patients with surgically treated benign prostatic hyperplasia.

Authors:  L Pientka; J van Loghem; E Hahn; H Guess; U Keil
Journal:  Urology       Date:  1991       Impact factor: 2.649

6.  Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

Authors:  B Lukacs; A Leplège; P Thibault; A Jardin
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

7.  A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.

Authors:  M J Naslund; A M Carlson; M J Williams
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia.

Authors:  J S Rasor; A R Zlotta; S D Edwards; C C Schulman
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

9.  Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice.

Authors:  B Lukacs; J C Grange; D Comet; C McCarthy
Journal:  Prostate Cancer Prostatic Dis       Date:  1998-09       Impact factor: 5.554

10.  Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

Authors:  Brian Hill; William Belville; Reginald Bruskewitz; Muta Issa; Ramon Perez-Marrero; Claus Roehrborn; Martha Terris; Michael Naslund
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  2 in total

1.  Impact of oral anticoagulation on morbidity of transurethral resection of the prostate.

Authors:  Aurélien Descazeaud; Gregoire Robert; Souhil Lebdai; Alain Bougault; Abdel Rahmene Azzousi; Olivier Haillot; Marian Devonec; Marc Fourmarier; Christian Saussine; Nicolas Barry-Delongchamps; Alexandre de la Taille
Journal:  World J Urol       Date:  2010-06-25       Impact factor: 4.226

Review 2.  [Benign prostatic hyperplasia (BPH) : Surgical therapy options].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; S Walther; C Stief
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.